Selected Cell
Cell:
Value:
include - 表格 1-2
Characteristics
Overall
AMSTAR 2
GRADE - pregnancy rate
GRADE - efficiency
GRADE - ovulation rate
GRADE - T
GRADE - LH
GRADE - FSH
GRADE - adverse effects
GRADE - LH_FSH
A
B
C
D
E
F
G
H
I
J
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
| Sifting | |||||||||
| Serial number | outcomes | fund | database | num of study | Total | T | C | Bias evaluation | |
| 42 | Relegation factors、Cycle ovulation rate、Improvement rate of menstruation、T、BMI | 3+ChiCTR+ICTR+embase+void+CENTRAL | 4 | 280 | Fu Fang Xuan Jv Jiao Nang+Western medicine | Western medicine | Cochranehandbook | ||
| 40 | efficiency、ovulation rate、Relegation factors | 3+pbmd+Cochran | 22 | 1763 | traditional medicine+Western medicine | Western medicine | Cochranehandbook | ||
| 39 | efficiency、Relegation factors、ovulation rate、LH、LH/FSH、T | 3+cbm | 13 | 1148 | traditional medicine+（Western medicine） | Western medicine | Cochranehandbook | ||
| 35 | efficiency、Relegation factors、ovulation rate、Cycle ovulation rate | 3+cmb+pbmd+embase | 12 | 1213 | traditional medicine+Western medicine | Western medicine | Jadad | ||
| 33 | ovulation rate、Relegation factors | 3 | 23 | - | traditional medicine+（Western medicine） | Western medicine | - | ||
| 32 | Relegation factors、ovulation rate、efficiency | 3 | 8 | - | 调周法+（Western medicine） | Western medicine | Jadad | ||
| 30 | 总efficiency、androgen、LH、LH/FSH、Relegation factors | Guangdong Provincial Science and Technology Planning Project（2014A020212273）； | 3+cbm+pbmd+co+sci | 22 | 1676 | Tonify the kidneytraditional medicine+Diane-35 | Diane-35 | Jadad | |
| 28 | efficiency、Relegation factors | Chinese medicine project of Jiangxi Health and Family Planning Commission【No.2015A087】； | 3+pbmd+medline+SpringerLink | 22 | - | traditional medicineTonify the kidneyInvigorate the blood法+（Western medicine） | Western medicine | Jadad | |
| 22 | efficiency、Relegation factors、Cycle ovulation rate | Medical Guidance Science and technology supporting project of Shanghai Science and Technology Commission（16401934500）；Shanghai School of Traditional Chinese medicine cai gynecological school heritage SR base（ZY3-CCCX-1-1006）； | 3 | 14 | 978 | traditional medicine人工Cycle +（Western medicine） | Western medicine | Jadad | |
| 21 | efficiency、ovulation rate、Cycle ovulation rate、Relegation factors | Surface Project of National Natural Science Foundation of China（No:81673661）； | 3+pbmd+Cochran | 14 | 1057 | 舒肝法+Western medicine | Western medicine | Cochranehandbook | |
| 20 | Relegation factors、ovulation rate | 3+pbmd+ovid | 11 | 1128 | KunTai capsule+Western medicine | Western medicine | Cochranehandbook | ||
| 19 | Relegation factors、ovulation rate、FSH、LH、T、Insulin content、 | 3+cbm+3 | 7 | 634 | traditional medicineTonify the kidneyInvigorate the blood法 | Clomifene Citrate | Cochranehandbook | ||
| 17 | efficiency、Relegation factors、ovulation rate、Ovarian volume、Number of mature follicles、LH、FSH、LH/FSH、E2、T | 3+cbm+2+medline | 34 | - | traditional medicineTonify the kidneyInvigorate the blood法+Western medicine | Western medicine | Cochranehandbook | ||
| 13 | efficiency、FSH、LH、LH/FSH、T、BMI、ovulation rate、physical sign score | Projects supported by the National Natural Science Foundation of China（No.81804135）； | 3+cbm+3 | 20 | 1484 | Cang Fu Dao Tan Tang+Western medicine | Western medicine | Jadad | |
| 12 | efficiency、ovulation rate、Relegation factors、estrogen、Degree of endometrial thickening | Surface Project of National Natural Science Foundation of China（No.81801466）； | 3+cbm+3 | 15 | 1259 | Fu Fang Xuan Jv Jiao Nang+Western medicine | Western medicine | Jadad | |
| 11 | efficiency、TCM syndrome、Relegation factors、Biphasic rate of basal body temperature、TCM syndrome socer、BMI、Acne score、LH、FSH、LH/FSH、T、E2、PRL、Insulin content、etc. | 3+cbm+3 | 43 | 3056 | traditional medicine | Western medicine | Cochranehandbook | ||
| 10 | efficiency、ovulation rate、Relegation factors、Number of mature follicles、Endometrial thickness、Cervical mucus score、FSH、LH、PRL、E2、T、P | National Natural Science Foundation of China（No:81802630） | 3+cmb+1 | 13 | 1305 | KunTai capsule+Letrozole | Letrozole | Jadad | |
| 8 | Relegation factors、Cycle ovulation rate、TCM syndrome、T、Endometrial thickness | Guangxi University of Chinese Medicine school-level research program（NO.2016MS009）;State Administration of Traditional Chinese Medicine | 3+Chi+pbmd+c | 14 | 1100 | Fu Fang Xuan Jv Jiao Nang+Western medicine | Western medicine | Cochranehandbook | |
| 7 | efficiency、ovulation rate、Relegation factors、T、LH、LH/FSH | 3+cbm+3+1 | 26 | 1299 | traditional medicine+Western medicine | Western medicine | Cochranehandbook | ||
| 4 | efficiency、Relegation factors、ovulation rate、Ovarian volume、T、LH、FSH | Natural Science Foundation of Fujian Province（NO.2019J01351）;Key projects supported by the Joint Fund of the National Natural Science Foundation of China（NO.U1705286） | 3+pbmd+Cochran | 7 | 502 | Gui Shen Wan+Western medicine | Western medicine | Cochranehandbook | |
| 2 | Endometrial thickness, endometrial type, uterine a pulsation index, uterine a resistance index、Relegation factorsTCM syndrome score、efficiency | State Administration of Traditional Chinese Medicine（1199ws02）Subject of Guangdong Traditional Chinese Medicine Bureau（20181120） | 3+1+3+1 | 13 | 797 | traditional medicine+Western medicine | Western medicine | CochraneCollaborationtools | |
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
| Characteristics | ||||||||||||||
| Serial number | Included Systematic Reviews | Number of databases | number of Include RCTs | Total subjects | Experimental group | Control group | Bias evaluation | fund | conclusion | 备注 | 库数 | |||
| 40 | Yan, Lun et al. 2015 | 4 | 13 | 1148 | Chinese medicine + (Western medicine) | Western medicine | Cochranehandbook | Tonify the kidneytraditional medicine联合CC治疗PCOS的临床效果高于单纯CC治疗PCOS的临床效果，其缓解率、ovulation rate、Relegation factors均有提高，并可降low未破裂卵泡黄素化综合征的发生率。但Tonify the kidneytraditional medicine治疗PCOS的机制尚未完全明确，有待进一步SR。 | 3+cbm | |||||
| 39 | Xiao Chao 2016 | 7 | 12 | 1213 | Chinese Medicine + Western Medicine | Western medicine | Jadad | 肾Invigorate the blood法或联合促排卵药对提高PCOS患者的总efficiency、Relegation factors，改善血清LH、LH/FSH、T水平，均有较好疗效;但没有足够的统计学证据证明Tonify the kidneyInvigorate the blood法或联合促排卵药在改善排卵方面的效果优于单纯使用促排卵药;Tonify the kidneyInvigorate the blood法治疗PCOS的安全性也有待进一步讨论。 | ovulation rate Not statistically significant | 3+cmb+pbmd+embase | ||||
| 35 | Li Nan et al. 2017 | 3 | 23 | - | Chinese medicine + (Western medicine) | Western medicine | - | 中西医结合治疗PCOS不孕症疗效较好，是一种具有发展前景的治疗方法。 | 3 | |||||
| 30 | Lu Ru-Ling et al. 2018 | 7 | 22 | 1676 | Kidney Tonic Herbs + Daing-35 | Daying-35 | Jadad | Guangdong Provincial Science and Technology Planning Project（2014A020212273）； | 现有证据显示Tonify the kidneytraditional medicine联合Diane-35治疗PCOS疗效显著，能明显改善性激素水平，提高总efficiency及Relegation factors，adverse effects少，可供临床参考与应用。 | 3+cbm+pbmd+co+sci | ||||
| 28 | Xu, Li-Fang et al. 2018 | 6 | 22 | - | Chinese medicine to tonify the kidneys and invigorate the blood + (Western medicine) | Western medicine | Jadad | Chinese medicine project of Jiangxi Health and Family Planning Commission【No.2015A087】； | Tonify the kidneyInvigorate the bloodtraditional medicine联合Western medicine治疗多囊卵巢综合征在改善临床症状、physical sign及妊娠方面明显优于单用Western medicine治疗，且中Western medicine联合应用安全性要明显高于Western medicine单用;而Tonify the kidneyInvigorate the bloodtraditional medicine单用于多囊卵巢综合征改善临床症状及physical sign上与Western medicine比较无明显优势，但在Relegation factors上有明显优势，但是由于纳入文献数量较少且文献质量 score较low，其有效性需要进一步观察及验证。 | 3+pbmd+medline+SpringerLink | ||||
| 22 | Xu Huayun et al. 2018 | 3 | 14 | 978 | Herbal manual cycle + (Western) | Western medicine | Jadad | Medical Guidance Science and technology supporting project of Shanghai Science and Technology Commission（16401934500）；Shanghai School of Traditional Chinese medicine cai gynecological school heritage SR base（ZY3-CCCX-1-1006）； | traditional medicine人工Cycle 治疗PCOS的疗效肯定，在efficiency、Relegation factors、Cycle ovulation rate方面优于单用Western medicine治疗，且未见明显adverse effects，但纳入的临床试验数量有限，在随机化、adverse effects报道等方面存在缺陷，建议进一步开展多中心、大样本、高质量的随机对照试验，并对adverse effects做充分的SR和报道。 | 3 | ||||
| 21 | Huang, Wenfang et al. 2018 | 5 | 14 | 1057 | Liver relaxation method + Western medicine | Western medicine | Cochranehandbook | Surface Project of National Natural Science Foundation of China（No:81673661）； | 运用疏肝法对肝郁型多囊卵巢综合征治疗后临床总efficiency以及ovulation rate、Cycle ovulation rate、Relegation factors均有显著提高，且效果优于Western medicine对照组，说明运用中医辨证治疗PCOS患者尤其要重视肝郁症，对临床治疗多囊卵巢综合征具有指导意义。 | 3+pbmd+Cochran | ||||
| 20 | Liu Ying et al. 2019 | 5 | 11 | 1128 | Kuntai capsule + Western medicine | Western medicine | Cochranehandbook | KunTai capsule联合用药能有效提高Relegation factors及ovulation rate，但要将其推广应用，尚需大样本、多中心的随机对照临床试验进一步证实。 | 3+pbmd+ovid | |||||
| 19 | Hara Bocchio 2019 | 7 | 7 | 634 | Chinese herbal remedies to tonify the kidneys and invigorate the blood | clomiphene | Cochranehandbook | Tonify the kidneyInvigorate the bloodtraditional medicine治疗多囊卵巢综合征导致不孕症临床疗效较好，安全性较高，但由于纳入文献SR质量相对偏low，结果可能存在偏倚，还需要更多高质量的临床研宄加以验证。 | ovulation rate Not statistically significant | 3+cbm+3 | ||||
| 17 | Ji Lin 2019 | 7 | 34 | - | Chinese medicine to tonify the kidneys and invigorate the blood + (Western medicine) | Western medicine | Cochranehandbook | 表明了Tonify the kidneyInvigorate the blood法治疗多囊卵巢综合征的疗效和安全性，为Tonify the kidneyInvigorate the blood法治疗多囊卵巢综合征提供了证据。 | FSH Not statistically significant | 3+cbm+2+medline | ||||
| 13 | Xie Peng Peng et al. 2019 | 7 | 20 | 1484 | Plus or minus Cang Fu Gui Phlegm Tang + Western medicine | Western medicine | Jadad | Projects supported by the National Natural Science Foundation of China（No.81804135）； | 对比单用化学药治疗PCOS，加减苍附导痰汤联合化学药可提高总efficiency和ovulation rate，降low血清激素水平、BMI指数及physical sign score。 | 3+cbm+3 | ||||
| 12 | Zhong Yizheng et al. 2019 | 7 | 15 | 1259 | Compound Xuanju Capsules + Western Medicine | Western medicine | Jadad | Surface Project of National Natural Science Foundation of China（No.81801466）； | Fu Fang Xuan Jv Jiao Nang联合化学药对比单用化学药治疗PCOS在提高总efficiency、ovulation rate、Relegation factors、子宫内膜增厚程度，降low血清estrogen水平方面均优于单用化学药。 | 3+cbm+3 | ||||
| 11 | Yufang Dong 2020 | 7 | 43 | 3056 | Chinese medicine | Western medicine | Cochranehandbook | 中医药组治疗多囊卵巢综合征的临床疗效总efficiency较Western medicine组好;中医药治疗能够提高临床治愈率、显效率，TCM syndrome疗效总efficiency、显效率，降lowTCM syndrome积分，促进正常月经恢复，进一步说明中医药治疗多囊卵巢综合征临床疗效确切。 | FSH Not statistically significant | 3+cbm+3 | ||||
| 10 | Li Nan et al. 2020 | 5 | 13 | 1305 | Kuntai capsule + Letrozole | letrozole (antibiotic) | Jadad | National Natural Science Foundation of China（No:81802630） | KunTai capsule联合Letrozole治疗PCOS的效果优于单药Letrozole治疗，可促进排卵，最终提高患者Relegation factors。但由于纳入试验的数量和质量原因，联合治疗的推广仍需更多高质量的临床随机试验的验证。 | 3+cmb+1 | ||||
| 8 | Du Xiu et al. 2020 | 6 | 14 | 1100 | Compound Xuanju Capsules + Western Medicine | Western medicine | Cochranehandbook | Guangxi University of Chinese Medicine school-level research program（NO.2016MS009）;State Administration of Traditional Chinese Medicine | Fu Fang Xuan Jv Jiao Nang是治疗多囊卵巢综合征不孕症的有效药物。但尚需更多大样本高质量临床试验予以验证。 | 3+Chi+pbmd+c | ||||
| 7 | Lim Bui Bui 2020 | 8 | 26 | 1299 | Chinese herbs + Western medicine for kidney and liver | Western medicine | Cochranehandbook | Tonify the kidney疏肝法治疗多囊卵巢综合征具有较好的临床疗效和安全性。 | 3+cbm+3+1 | |||||
| 4 | Chan Kam Ming et al. 2020 | 5 | 7 | 502 | Guei Ren Pills + Western Medicine | Western medicine | Cochranehandbook | Natural Science Foundation of Fujian Province（NO.2019J01351）;Key projects supported by the Joint Fund of the National Natural Science Foundation of China（NO.U1705286） | 与常规Western medicine相比，归肾丸联合常规Western medicine在PCOS的治疗中能显著改善患者的Relegation factors、ovulation rate、Ovarian volume和性激素水平，且安全性良好。 | FSH Not statistically significant | 3+pbmd+Cochran | |||
| 2 | Huang Ting et al. 2020 | 8 | 13 | 797 | Kidney Tonic Herbs + Clomiphene | clomiphene | Cochranehandbook | State Administration of Traditional Chinese Medicine（1199ws02）Subject of Guangdong Traditional Chinese Medicine Bureau（20181120） | 对比单纯使用克罗米芬，Tonify the kidneytraditional medicine联合克罗米芬能有效促进PCOS患者的子宫内膜增长，并改善其子宫内膜类型，促进子宫内膜血流灌注，提高Relegation factors，同时改善临床症状，降lowTCM syndrome score，提高治疗总efficiency。 | 3+1+3+1 | ||||
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
AA
AB
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
| 表格 1 | |||||||||||||||||||||||||||
| Serial number | Included Systematic Reviews | Experimental group | Control group | Relegation factors | Relegation factorsGRADE quality of evidence | Relegation factorsRelegation factors | efficiency | efficiencyGRADE quality of evidence | efficiencyRelegation factors | ovulation rate | ovulation rateGRADE quality of evidence | ovulation rateRelegation factors | T | T | T | LH | LH | LH | FSH | FSH | FSH | L/F | L/F | L/F | adverse effects | conclusion | 备注 |
| 40 | Yan, Lun et al. 2015 | Chinese medicine + (Western medicine) | Western medicine | OR=3.44，95%CI(2.66，4.43) | low16 | ①④ | OR=5.32，95%CI(3.82，7.41) | low14 | ①④ | OR=2.18，95%CI(1.63，2.92) | very low9 | ①④⑤ | - | - | - | - | - | - | - | - | - | - | - | - | OR=0.19，95%CI(0.08，0.46)low4①⑤ | Tonify the kidneytraditional medicine联合CC治疗PCOS的临床效果高于单纯CC治疗PCOS的临床效果，其缓解率、ovulation rate、Relegation factors均有提高，并可降low未破裂卵泡黄素化综合征的发生率。但Tonify the kidneytraditional medicine治疗PCOS的机制尚未完全明确，有待进一步SR。 | |
| 39 | Xiao Chao 2016 | Chinese Medicine + Western Medicine | Western medicine | RR=1.91，95%CI(1.59，2.29) | low9 | ①⑤ | RR=1.27，95%CI(1.19，1.36) | low7 | ①⑤ | RR=1.10，95%CI(0.87，1.39) | very low8 | ①②④⑤ | SMD=-0.81，95%CI(-1.46，-0.16) | very low8 | ①②④⑤ | SMD=-1.16，95%CI(-1.66，-0.66) | very low7 | ①②④⑤ | - | - | - | MD=-0.81，95%CI(-1.17，-0.45) | very low4 | ①②④⑤ | RD=-0.05，95%CI(-0.13，0.03)very low4①②⑤ | 肾Invigorate the blood法或联合促排卵药对提高PCOS患者的总efficiency、Relegation factors，改善血清LH、LH/FSH、T水平，均有较好疗效;但没有足够的统计学证据证明Tonify the kidneyInvigorate the blood法或联合促排卵药在改善排卵方面的效果优于单纯使用促排卵药;Tonify the kidneyInvigorate the blood法治疗PCOS的安全性也有待进一步讨论。 | ovulation rate Not statistically significant |
| 35 | Li Nan et al. 2017 | Chinese medicine + (Western medicine) | Western medicine | OR=2.96，95%CI(2.35，3.74) | very low12 | ①④⑤ | OR=3.90，95%CI(2.92，5.20) | low8 | ①④ | OR=2.70，95%CI(1.32，5.45) | very low6 | ①②④⑤ | - | - | - | - | - | - | - | - | - | - | - | - | OR=0.07，95%CI(0.02，0.23)very low3①②④⑤ | 中西医结合治疗PCOS不孕症疗效较好，是一种具有发展前景的治疗方法。 | |
| 30 | Lu Ru-Ling et al. 2018 | Kidney Tonic Herbs + Daing-35 | Daying-35 | OR=3.34，95%CI(2.23，5.02) | very low8 | ①②④⑤ | OR=4.22，95%CI(2.86，6.23) | very low11 | ①④⑤ | - | - | - | - | - | - | MD=-1.84，95%CI(-1.98，-1.70) | very low18 | ①②⑤ | - | - | - | MD=-0.25，95%CI(-0.44，-0.06) | very low12 | ①②⑤ | 现有证据显示Tonify the kidneytraditional medicine联合Diane-35治疗PCOS疗效显著，能明显改善性激素水平，提高总efficiency及Relegation factors，adverse effects少，可供临床参考与应用。 | ||
| 28 | Xu, Li-Fang et al. 2018 | Chinese medicine to tonify the kidneys and invigorate the blood + (Western medicine) | Western medicine | OR=3.83，95%CI(2.95，4.96) | very low18 | ①④⑤ | OR=2.83，95%CI(2.06，3.88) | very low18 | ①④⑤ | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | OR=0.26，95%CI(0.09，0.80)low10①⑤ | Tonify the kidneyInvigorate the bloodtraditional medicine联合Western medicine治疗多囊卵巢综合征在改善临床症状、physical sign及妊娠方面明显优于单用Western medicine治疗，且中Western medicine联合应用安全性要明显高于Western medicine单用;而Tonify the kidneyInvigorate the bloodtraditional medicine单用于多囊卵巢综合征改善临床症状及physical sign上与Western medicine比较无明显优势，但在Relegation factors上有明显优势，但是由于included RCTs量较少且文献质量 score较low，其有效性需要进一步观察及验证。 | |
| 22 | Xu Huayun et al. 2018 | Herbal manual cycle + (Western) | Western medicine | RR=1.70，95%CI(1.39，2.09) | Moderate11 | ① | RR=1.19，95%CI(0.87，1.63) | low13 | ①⑤ | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | traditional medicine人工Cycle 治疗PCOS的疗效肯定，在efficiency、Relegation factors、Cycle ovulation rate方面优于单用Western medicine治疗，且未见明显adverse effects，但纳入的临床试验数量有限，在随机化、adverse effects报道等方面存在缺陷，建议进一步开展多中心、大样本、高质量的随机对照试验，并对adverse effects做充分的SR和报道。 | ||
| 21 | Huang, Wenfang et al. 2018 | Liver relaxation method + Western medicine | Western medicine | OR=1.97，95%CI(1.19，3.25) | very low3 | ①④⑤ | OR=2.63，95%CI(1.67，4.15) | very low7 | ①④⑤ | OR=2.18，95%CI(1.77，2.68) | low6 | ①⑤ | - | - | - | - | - | - | - | - | - | - | - | - | 运用疏肝法对肝郁型多囊卵巢综合征治疗后临床总efficiency以及ovulation rate、Cycle ovulation rate、Relegation factors均有显著提高，且效果优于Western medicine对照组，说明运用中医辨证治疗PCOS患者尤其要重视肝郁症，对临床治疗多囊卵巢综合征具有指导意义。 | ||
| 20 | Liu Ying et al. 2019 | Kuntai capsule + Western medicine | Western medicine | RR=1.71，95%CI(1.46，2.01) | low11 | ①⑤ | - | - | - | RR=1.34，95%CI(1.23，1.46) | low8 | ①⑤ | - | - | - | - | - | - | - | - | - | - | - | - | KunTai capsule联合用药能有效提高Relegation factors及ovulation rate，但要将其推广应用，尚需大样本、多中心的随机对照临床试验进一步证实。 | ||
| 19 | Hara Bocchio 2019 | Chinese herbal remedies to tonify the kidneys and invigorate the blood | clomiphene | RR=1.78，95%CI(1.44，2.19) | low7 | ①⑤ | - | - | - | RR=0.97，95%CI(0.86，1.09) | very low6 | ①②④⑤ | MD=-1.51，95%CI(-1.64，-1.37) | very low5 | ①④⑤ | MD=-6.72，95%CI(-7.32，-6.13) | very low5 | ①④⑤ | - | - | - | - | - | - | Tonify the kidneyInvigorate the bloodtraditional medicine治疗多囊卵巢综合征导致不孕症临床疗效较好，安全性较高，但由于纳入文献SR质量相对偏low，结果可能存在偏倚，还需要更多高质量的临床研宄加以验证。 | ovulation rate Not statistically significant | |
| 17 | Ji Lin 2019 | Chinese medicine to tonify the kidneys and invigorate the blood + (Western medicine) | Western medicine | OR=2.78，95%CI(2.21，3.51) | low17 | ①④ | OR=3.38，95%CI(2.59，4.41) | Moderate | ① | OR=1.92，95%CI(1.40，2.64) | low14 | ①② | SMD=-0.64，95%CI(-0.97，-0.36) | very low24 | ①②⑤ | SMD=-0.55，95%CI(-0.74，-0.37) | low23 | ①④ | SMD=0.12，95%CI(-0.29，-0.53) | very low19 | ①②④ | SMD=-0.45，95%CI(-0.68，-0.23) | low11 | ①② | OR=0.26，95%CI(0.12，0.55)very low13①②⑤ | 表明了Tonify the kidneyInvigorate the blood法治疗多囊卵巢综合征的疗效和安全性，为Tonify the kidneyInvigorate the blood法治疗多囊卵巢综合征提供了证据。 | FSH Not statistically significant |
| 13 | Xie Peng Peng et al. 2019 | Plus or minus Cang Fu Gui Phlegm Tang + Western medicine | Western medicine | - | - | - | RR=1.13，95%CI(1.02，1.24) | Moderate | ① | RR=1.17，95%CI(1.02，1.34) | low10 | ①④ | WMD=-0.93，95%CI(-1.38，-0.28) | very low13 | ①②④⑤ | WMD=-0.95，95%CI(-1.41，-0.52) | very low13 | ①②④ | WMD=-0.59，95%CI(-0.98，-0.20) | very low11 | ①②④ | WMD=-1.04，95%CI(-1.78，-0.33) | very low3 | ①②④⑤ | 对比单用化学药治疗PCOS，加减苍附导痰汤联合化学药可提高总efficiency和ovulation rate，降low血清激素水平、BMI指数及physical sign score。 | ||
| 12 | Zhong Yizheng et al. 2019 | Compound Xuanju Capsules + Western Medicine | Western medicine | RR=1.34，95%CI(1.11，1.61) | low6 | ①④ | RR=1.27，95%CI(1.13，1.44) | Moderate | ① | RR=1.18，95%CI(1.03，1.37) | low5 | ①④ | SMD=-1.59，95%CI(-1.76，-1.41) | very low9 | ①②④ | SMD=-1.24，95%C(I-1.39，-1.08) | very low9 | ①②④ | SMD=0.66，95%CI(0.51，0.82) | low8 | ①④ | - | - | - | Fu Fang Xuan Jv Jiao Nang联合化学药对比单用化学药治疗PCOS在提高总efficiency、ovulation rate、Relegation factors、子宫内膜增厚程度，降low血清estrogen水平方面均优于单用化学药。 | ||
| 11 | Yufang Dong 2020 | Chinese medicine | Western medicine | RR=1.94，95%CI(1.14，3.29) | very low8 | ①④⑤ | RR=1.26，95%CI(1.20，1.32) | Moderate | ① | - | - | - | SMD=-0.40，95%CI(-0.65，-0.15) | very low37 | ①②④ | SMD=-0.38，95%CI(-0.59，-0.16) | very low39 | ①②④ | SMD=0.01，95%CI(-0.22，0.25) | very low37 | ①②④⑤ | SMD=-0.39，95%CI(-0.60，-0.19) | very low22 | ①②④ | RR=0.12，95%CI(0.06，0.25)low8①④ | 中医药组治疗多囊卵巢综合征的临床疗效总efficiency较Western medicine组好;中医药治疗能够提高临床治愈率、显效率，TCM syndrome疗效总efficiency、显效率，降lowTCM syndrome积分，促进正常月经恢复，进一步说明中医药治疗多囊卵巢综合征临床疗效确切。 | FSH Not statistically significant |
| 10 | Li Nan et al. 2020 | Kuntai capsule + Letrozole | letrozole (antibiotic) | OR=2.49，95%CI(1.79，3.45) | very low8 | ①④⑤ | OR=3.42，95%CI(1.76，6.64) | very low4 | ①④⑤ | OR=3.91，95%CI(1.95，7.84) | very low4 | ①④⑤ | SMD=-0.68，95%CI(-3.99，2.62) | very low3 | ①②④⑤ | SMD=1.67，95%CI(-1.97，-1.37) | very low5 | ①②④ | SMD=-1.67，95%CI(-3.05，-0.30) | very low5 | ①②④⑤ | - | - | - | KunTai capsule联合Letrozole治疗PCOS的效果优于单药Letrozole治疗，可促进排卵，最终提高患者Relegation factors。但由于纳入试验的数量和质量原因，联合治疗的推广仍需更多高质量的临床随机试验的验证。 | ||
| 8 | Du Xiu et al. 2020 | Compound Xuanju Capsules + Western Medicine | Western medicine | RR=1.68，95%CI(1.45，1.94) | Moderate14 | ① | - | - | - | RR=1.17，95%CI(1.03，1.34) | very low6 | ①②④ | RR=-0.53，95%CI(-0.90，-0.16) | very low5 | ①②④ | - | - | - | - | - | - | - | - | - | Fu Fang Xuan Jv Jiao Nang是治疗多囊卵巢综合征不孕症的有效药物。但尚需更多大样本高质量临床试验予以验证。 | ||
| 7 | Lim Bui Bui 2020 | Chinese herbs + Western medicine for kidney and liver | Western medicine | RR=1.69，95%CI(1.45，1.98) | low14 | ①④ | RR=1.26，95%CI(1.17，1.36) | very low18 | ①②④ | RR=1.31，95%CI(1.16，1.48) | low6 | ①④ | SMD=-0.20，95%CI(-0.55，0.16) | very low19 | ①②④⑤ | SMD=-0.78，95%CI(-1.22，-0.34) | very low17 | ①②④ | - | - | - | MD=-0.37，95%CI(-0.53，-0.21) | very low14 | ①②④ | RR=0.36，95%CI(0.20，0.63)low13①④ | Tonify the kidney疏肝法治疗多囊卵巢综合征具有较好的临床疗效和安全性。 | |
| 4 | Chan Kam Ming et al. 2020 | Guei Ren Pills + Western Medicine | Western medicine | RR=1.56，95%CI(1.27，1.91) | low6 | ①④ | RR=1.26，95%CI(1.15，1.37) | low6 | ①④ | RR=1.21，95%CI(1.07，1.37) | very low3 | ①④⑤ | MD=0.95，95%CI(0.15，1.75) | very low2 | ①②④⑤ | MD=7.55，95%CI(2.05，13.04) | very low2 | ①②④⑤ | MD=0.13，95%CI(-0.39，0.66) | very low2 | ①②④⑤ | - | - | - | 与常规Western medicine相比，归肾丸联合常规Western medicine在PCOS的治疗中能显著改善患者的Relegation factors、ovulation rate、Ovarian volume和性激素水平，且安全性良好。 | FSH Not statistically significant | |
| 2 | Huang Ting et al. 2020 | Kidney Tonic Herbs + Clomiphene | clomiphene | RR=2.18，95%CI(1.55，3.05) | very low8 | ①④⑤ | RR=1.25;95%CI(1.13，1.37) | very low8 | ①④⑤ | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | Tonify the kidneytraditional medicine联合克罗米芬组中出现3例口干、4例头晕，克罗米芬组中出现2例头痛、2例便秘、1例皮疹、1例卵巢过度刺激综合征、1例脱发、1例未破裂卵泡黄素化综合征 | 对比单纯使用克罗米芬，Tonify the kidneytraditional medicine联合克罗米芬能有效促进PCOS患者的子宫内膜增长，并改善其子宫内膜类型，促进子宫内膜血流灌注，提高Relegation factors，同时改善临床症状，降lowTCM syndrome score，提高治疗总efficiency。 | |
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
| AMSTAR 2 | |||||||||||||||||||
| Included Systematic Reviews | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | Credibility | ||
| 40 | Yan, Lun et al. 2015 | Y | N | N | Y | Y | N | N | PY | N | N | Y | NP | N | Y | Y | N | Very low | |
| 39 | Xiao Chao 2016 | Y | N | N | Y | Y | N | N | Y | Y | N | N | Y | Y | N | Y | N | Very low | |
| 35 | Li Nan et al. 2017 | Y | N | N | Y | Y | N | N | PY | N | N | N | NP | N | N | NP | N | Very low | |
| 30 | Ruling Lu et al. 2018 | Y | N | N | Y | Y | N | N | PY | Y | N | N | N | N | N | Y | N | Very low | |
| 28 | Xu, Li-Fang et al. 2018 | Y | N | N | Y | N | N | N | PY | Y | N | N | N | N | Y | Y | N | Very low | |
| 22 | Xu Huayun et al. 2018 | Y | N | N | Y | Y | Y | N | PY | Y | N | N | Y | Y | N | Y | N | Very low | |
| 21 | Huang, Wenfang et al. 2018 | Y | N | N | Y | Y | Y | N | PY | Y | N | Y | Y | Y | Y | Y | N | Very low | |
| 20 | Liu Ying et al. 2019 | Y | N | N | Y | Y | N | N | PY | Y | N | Y | NP | NP | Y | N | N | Very low | |
| 19 | Original Bochao 2019 | Y | N | N | Y | Y | Y | N | PY | Y | N | NP | Y | Y | N | N | N | Very low | |
| 17 | Jilin 2019 | Y | N | N | Y | Y | Y | N | PY | Y | N | Y | Y | Y | Y | Y | N | Very low | |
| 13 | Xie Peng Peng et al 2019 | Y | N | N | Y | Y | Y | N | PY | Y | N | N | Y | Y | N | Y | N | Very low | |
| 12 | Zhong Yizheng et al. 2019 | Y | N | N | Y | Y | Y | N | PY | Y | N | Y | Y | Y | Y | Y | N | Very low | |
| 11 | Tung Yu Fong 2020 | Y | N | N | Y | Y | Y | N | PY | Y | N | N | Y | Y | N | Y | N | Very low | |
| 10 | Li Nan et al. 2020 | Y | N | N | Y | Y | Y | N | PY | Y | N | Y | NP | N | Y | NP | N | Very low | |
| 8 | Du Xiu et al. 2020 | Y | N | N | Y | Y | Y | N | PY | Y | N | N | NP | N | N | Y | N | Very low | |
| 7 | Limpibe 2020 | Y | N | N | Y | Y | Y | N | PY | Y | N | N | NP | Y | N | Y | N | Very low | |
| 4 | Chan Kam Ming 2020 | Y | N | N | Y | Y | Y | N | PY | Y | N | Y | NP | N | Y | NP | N | Very low | |
| 2 | Wong Ting Ting 2020 | Y | N | N | Y | Y | Y | N | PY | Y | N | N | Y | Y | N | N | N | Very low | |
| Percentage of reports | 1 | 0 | 0 | 1 | 0.94 | 0.67 | 0 | 1 | 0.89 | 0 | 0.39 | 0.5 | 0.56 | 0.44 | 0.67 | 0 | |||
A
B
C
D
E
F
G
H
I
J
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
| pregnancy rate | |||||||||
| SR | include RCTs | pregnancy rate | GRADE quality of evidence | Relegation factors | |||||
| 40 | Yan, Lun et al. 2015 | 16 | OR=3.44，95%CI(2.66，4.43) | low | ①④ | ||||
| 39 | Xiao Chao 2016 | 9 | RR=1.91，95%CI(1.59，2.29) | low | ①⑤ | ||||
| 35 | Li Nan et al. 2017 | 12 | OR=2.96，95%CI(2.35，3.74) | very low | ①④⑤ | ||||
| 30 | Ruling Lu et al. 2018 | 8 | OR=3.34，95%CI(2.23，5.02) | very low | ①②④⑤ | ||||
| 28 | Xu, Li-Fang et al. 2018 | 18 | OR=3.83，95%CI(2.95，4.96) | very low | ①④⑤ | ||||
| 22 | Xu Huayun et al. 2018 | 11 | RR=1.70，95%CI(1.39，2.09) | Moderate | ① | ||||
| 21 | Huang, Wenfang et al. 2018 | 3 | OR=1.97，95%CI(1.19，3.25) | very low | ①④⑤ | ||||
| 20 | Liu Ying et al. 2019 | 11 | RR=1.71，95%CI(1.46，2.01) | low | ①⑤ | ||||
| 19 | Original Bochao 2019 | 7 | RR=1.78，95%CI(1.44，2.19) | low | ①⑤ | ||||
| 17 | Jilin 2019 | 17 | OR=2.78，95%CI(2.21，3.51) | low | ①④ | ||||
| 12 | Zhong Yizheng et al. 2019 | 6 | RR=1.34，95%CI(1.11，1.61) | low | ①④ | ||||
| 11 | Tung Yu Fong 2020 | 8 | RR=1.94，95%CI(1.14，3.29) | very low | ①④⑤ | ||||
| 10 | Li Nan et al. 2020 | 8 | OR=2.49，95%CI(1.79，3.45) | very low | ①④⑤ | ||||
| 8 | Du Xiu et al. 2020 | 14 | RR=1.68，95%CI(1.45，1.94) | Moderate | ① | ||||
| 7 | Limpibe 2020 | 14 | RR=1.69，95%CI(1.45，1.98) | low | ①④ | ||||
| 4 | Chan Kam Ming et al. 2020 | 6 | RR=1.56，95%CI(1.27，1.91) | low | ①④ | ||||
| 2 | Huang Ting et al. 2020 | 8 | RR=2.18，95%CI(1.55，3.05) | very low | ①④⑤ | ||||
A
B
C
D
E
F
G
H
I
J
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
| efficiency | |||||||||
| SR | include RCTs | efficiency | GRADE quality of evidence | Relegation factors | |||||
| 40 | Yan, Lun et al. 2015 | 14 | OR=5.32，95%CI(3.82，7.41) | low | ①④ | ||||
| 39 | Xiao Chao 2016 | 7 | RR=1.27，95%CI(1.19，1.36) | low | ①⑤ | ||||
| 35 | Li Nan et al. 2017 | 8 | OR=3.90，95%CI(2.92，5.20) | low | ①④ | ||||
| 30 | Ruling Lu et al. 2018 | 11 | OR=4.22，95%CI(2.86，6.23) | very low | ①④⑤ | ||||
| 28 | Xu, Li-Fang et al. 2018 | 18 | OR=2.83，95%CI(2.06，3.88) | very low | ①④⑤ | ||||
| 22 | Xu Huayun et al. 2018 | 13 | RR=1.19，95%CI(0.87，1.63) | low | ①⑤ | ||||
| 21 | Huang, Wenfang et al. 2018 | 7 | OR=2.63，95%CI(1.67，4.15) | very low | ①④⑤ | ||||
| 17 | Jilin 2019 | 21 | OR=3.38，95%CI(2.59，4.41) | Moderate | ① | ||||
| 13 | Xie Peng Peng et al 2019 | 14 | RR=1.13，95%CI(1.02，1.24) | Moderate | ① | ||||
| 12 | Zhong Yizheng et al. 2019 | 10 | RR=1.27，95%CI(1.13，1.44) | Moderate | ① | ||||
| 11 | Tung Yu Fong 2020 | 31 | RR=1.26，95%CI(1.20，1.32) | Moderate | ① | ||||
| 10 | Li Nan et al. 2020 | 4 | OR=3.42，95%CI(1.76，6.64) | very low | ①④⑤ | ||||
| 7 | Limpibe 2020 | 18 | RR=1.26，95%CI(1.17，1.36) | very low | ①②④ | ||||
| 4 | Chan Kam Ming et al. 2020 | 6 | RR=1.26，95%CI(1.15，1.37) | low | ①④ | ||||
| 2 | Huang Ting et al. 2020 | 8 | RR=1.25，95%CI(1.13，1.37) | very low | ①④⑤ | ||||
A
B
C
D
E
F
G
H
I
J
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
| ovulation rate | |||||||||
| SR | include RCTs | ovulation rate | GRADE quality of evidence | Relegation factors | |||||
| 40 | Yan, Lun et al. 2015 | 9 | OR=2.18，95%CI(1.63，2.92) | very low | ①④⑤ | ||||
| 39 | Xiao Chao 2016 | 8 | RR=1.10，95%CI(0.87，1.39) | very low | ①②④⑤ | ||||
| 35 | Li Nan et al. 2017 | 6 | OR=2.70，95%CI(1.32，5.45) | very low | ①②④⑤ | ||||
| 21 | Huang, Wenfang et al. 2018 | 6 | OR=2.18，95%CI(1.77，2.68) | low | ①⑤ | ||||
| 20 | Liu Ying et al. 2019 | 8 | RR=1.34，95%CI(1.23，1.46) | low | ①⑤ | ||||
| 19 | Original Bochao 2019 | 6 | RR=0.97，95%CI(0.86，1.09) | very low | ①②④⑤ | ||||
| 17 | Jilin 2019 | 14 | OR=1.92，95%CI(1.40，2.64) | low | ①② | ||||
| 13 | Xie Peng Xin et al 2019 | 10 | RR=1.17，95%CI(1.02，1.34) | low | ①④ | ||||
| 12 | Zhong Yizheng et al. 2019 | 5 | RR=1.18，95%CI(1.03，1.37) | low | ①④ | ||||
| 10 | Li Nan et al. 2020 | 4 | OR=3.91，95%CI(1.95，7.84) | very low | ①④⑤ | ||||
| 8 | Du Xiu et al. 2020 | 6 | RR=1.17，95%CI(1.03，1.34) | very low | ①②④ | ||||
| 7 | Limpibe 2020 | 6 | RR=1.31，95%CI(1.16，1.48) | low | ①④ | ||||
| 4 | Chan Kam Ming et al. 2020 | 3 | RR=1.21，95%CI(1.07，1.37) | very low | ①④⑤ | ||||
A
B
C
D
E
F
G
H
I
J
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
| T | |||||||||
| SR | include RCTs | T | GRADE quality of evidence | Relegation factors | |||||
| 39 | Xiao Chao 2016 | 8 | SMD=-0.81，95%CI(-1.46，-0.16) | very low | ①②④⑤ | ||||
| 19 | Original Bochao 2019 | 5 | MD=-1.51，95%CI(-1.64，-1.37) | very low | ①④⑤ | ||||
| 17 | Jilin 2019 | 24 | SMD=-0.64，95%CI(-0.97，-0.36) | very low | ①②⑤ | ||||
| 13 | Xie Peng Peng et al 2019 | 13 | WMD=-0.93，95%CI(-1.38，-0.28) | very low | ①②④⑤ | ||||
| 12 | Zhong Yizheng et al. 2019 | 9 | SMD=-1.59，95%CI(-1.76，-1.41) | very low | ①②④ | ||||
| 11 | Tung Yu Fong 2020 | 37 | SMD=-0.40，95%CI(-0.65，-0.15) | very low | ①②④ | ||||
| 10 | Li Nan et al. 2020 | 3 | SMD=-0.68，95%CI(-3.99，2.62) | very low | ①②④⑤ | ||||
| 8 | Du Xiu et al. 2020 | 5 | RR=-0.53，95%CI(-0.90，-0.16) | very low | ①②④ | ||||
| 7 | Limpibe 2020 | 19 | SMD=-0.20，95%CI(-0.55，0.16) | very low | ①②④⑤ | ||||
| 4 | Chan Kam Ming et al. 2020 | 2 | MD=0.95，95%CI(0.15，1.75) | very low | ①②④⑤ | ||||
A
B
C
D
E
F
G
H
I
J
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
| LH | |||||||||
| SR | include RCTs | LH | GRADE quality of evidence | Relegation factors | |||||
| 39 | Xiao Chao 2016 | 7 | SMD=-1.16，95%CI(-1.66，-0.66) | very low | ①②④⑤ | ||||
| 30 | Ruling Lu et al. 2018 | 18 | MD=-1.84，95%CI(-1.98，-1.70) | very low | ①②⑤ | ||||
| 19 | Original Bochao 2019 | 5 | MD=-6.72，95%CI(-7.32，-6.13) | very low | ①④⑤ | ||||
| 17 | Jilin 2019 | 23 | SMD=-0.55，95%CI(-0.74，-0.37) | low | ①④ | ||||
| 13 | Xie Peng Peng et al 2019 | 13 | WMD=-0.95，95%CI(-1.41，-0.52) | very low | ①②④ | ||||
| 12 | Zhong Yizheng et al. 2019 | 9 | SMD=-1.24，95%CI(-1.39，-1.08) | very low | ①②④ | ||||
| 11 | Tung Yu Fong 2020 | 39 | SMD=-0.38，95%CI(-0.59，-0.16) | very low | ①②④ | ||||
| 10 | Li Nan et al. 2020 | 5 | SMD=1.67，95%CI(-1.97，-1.37) | very low | ①②④ | ||||
| 7 | Limpibe 2020 | 17 | SMD=-0.78，95%CI(-1.22，-0.34) | very low | ①②④ | ||||
| 4 | Chan Kam Ming et al. 2020 | 2 | MD=7.55，95%CI(2.05，13.04) | very low | ①②④⑤ | ||||
A
B
C
D
E
F
G
H
I
J
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
| FSH | |||||||||
| 17 | Jilin 2019 | 19 | SMD=0.12，95%CI(-0.29，-0.53) | very low | ①②④ | ||||
| 13 | Xie Peng Peng et al 2019 | 11 | WMD=-0.59，95%CI(-0.98，-0.20) | very low | ①②④ | ||||
| 12 | Zhong Yizheng et al. 2019 | 8 | SMD=0.66，95%CI(0.51，0.82) | low | ①④ | ||||
| 11 | Tung Yu Fong 2020 | 37 | SMD=0.01，95%CI(-0.22，0.25) | very low | ①②④⑤ | ||||
| 10 | Li Nan et al. 2020 | 5 | SMD=-1.67，95%CI(-3.05，-0.30) | very low | ①②④⑤ | ||||
| 4 | Chan Kam Ming et al. 2020 | 2 | MD=0.13，95%CI(-0.39，0.66) | very low | ①②④⑤ | ||||
A
B
C
D
E
F
G
H
I
J
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
| adverse effects | |||||||||
| SR | include RCTs | adverse effects | GRADE quality of evidence | Relegation factors | |||||
| 40 | Yan, Lun et al. 2015 | 4 | OR=0.19，95%CI(0.08，0.46) | low | ①⑤ | ||||
| 39 | Xiao Chao 2016 | 4 | RD=-0.05，95%CI(-0.13，0.03) | very low | ①②⑤ | ||||
| 35 | Li Nan et al. 2017 | 3 | OR=0.07，95%CI(0.02，0.23) | very low | ①②④⑤ | ||||
| 28 | Xu, Li-Fang et al. 2018 | 10 | OR=0.26，95%CI(0.09，0.80) | low | ①⑤ | ||||
| 17 | Jilin 2019 | 13 | OR=0.26，95%CI(0.12，0.55) | very low | ①②⑤ | ||||
| 11 | Tung Yu Fong 2020 | 8 | RR=0.12，95%CI(0.06，0.25) | low | ①④ | ||||
| 7 | Limpibe 2020 | 13 | RR=0.36，95%CI(0.20，0.63) | low | ①④ | ||||
A
B
C
D
E
F
G
H
I
J
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
| LH/FSH | |||||||||
| SR | include RCTs | L/F | GRADE quality of evidence | Relegation factors | |||||
| 39 | Xiao Chao 2016 | 4 | MD=-0.81，95%CI(-1.17，-0.45) | very low | ①②④⑤ | ||||
| 30 | Ruling Lu et al. 2018 | 12 | MD=-0.25，95%CI(-0.44，-0.06) | very low | ①②⑤ | ||||
| 17 | Jilin 2019 | 11 | SMD=-0.45，95%CI(-0.68，-0.23) | low | ①② | ||||
| 13 | Xie Peng Peng et al 2019 | 3 | WMD=-1.04，95%CI(-1.78，-0.33) | very low | ①②④⑤ | ||||
| 11 | Tung Yu Fong 2020 | 22 | SMD=-0.39，95%CI(-0.60，-0.19) | very low | ①②④ | ||||
| 7 | Limpibe 2020 | 14 | MD=-0.37，95%CI(-0.53，-0.21) | very low | ①②④ | ||||
